A Study of LY3305677 in Participants With Obesity Or Overweight
Status:
Not yet recruiting
Trial end date:
2023-06-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn about the safety and tolerability of LY3305677
when given to participants with obesity or overweight. Blood tests will be performed to
investigate how the body processes the study drug and how the study drug affects the body.
Each enrolled participant will receive injections of LY3305677 or placebo given just under
the skin. For each participant, the study will last about approximately 28 weeks.